340 related articles for article (PubMed ID: 25935863)
21. The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.
von Scholten BJ; Ørsted DD; Svendsen AL; Persson F; Rossing P
J Diabetes Complications; 2015; 29(8):1146-51. PubMed ID: 26345339
[TBL] [Abstract][Full Text] [Related]
22. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.
Usui R; Yabe D; Kuwata H; Murotani K; Kurose T; Seino Y
J Diabetes Complications; 2015; 29(8):1203-10. PubMed ID: 26279320
[TBL] [Abstract][Full Text] [Related]
24. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
25. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
Skov J; Pedersen M; Holst JJ; Madsen B; Goetze JP; Rittig S; Jonassen T; Frøkiaer J; Dejgaard A; Christiansen JS
Diabetes Obes Metab; 2016 Jun; 18(6):581-9. PubMed ID: 26910107
[TBL] [Abstract][Full Text] [Related]
26. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
27. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Michos ED; Tuttle KR
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
[No Abstract] [Full Text] [Related]
28. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
[TBL] [Abstract][Full Text] [Related]
29. Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.
Hiramatsu T; Ozeki A; Ishikawa H; Furuta S
Drug Res (Stuttg); 2017 Nov; 67(11):640-646. PubMed ID: 28738426
[No Abstract] [Full Text] [Related]
30. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
[TBL] [Abstract][Full Text] [Related]
31. Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.
Jørgensen PG; Jensen MT; Mensberg P; Storgaard H; Nyby S; Jensen JS; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Jul; 19(7):1040-1044. PubMed ID: 28188972
[TBL] [Abstract][Full Text] [Related]
32. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Li Q; Jia M; Yan Z; Li Q; Sun F; He C; Li Y; Zhou X; Zhang H; Liu X; Bu X; Gao P; He H; Zhao Z; Zhu Z
J Am Heart Assoc; 2021 Jul; 10(14):e020734. PubMed ID: 34250817
[TBL] [Abstract][Full Text] [Related]
33. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
Zavattaro M; Caputo M; Samà MT; Mele C; Chasseur L; Marzullo P; Pagano L; Mauri MG; Ponziani MC; Aimaretti G; Prodam F
Endocrine; 2015 Dec; 50(3):620-6. PubMed ID: 25572181
[TBL] [Abstract][Full Text] [Related]
34. Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB;
N Engl J Med; 2017 Aug; 377(9):839-848. PubMed ID: 28854085
[TBL] [Abstract][Full Text] [Related]
35. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Tack CJ; Jacob S; Desouza C; Bain SC; Buse JB; Nauck MA; Petrie JR; Poulter NR; Pratley RE; Stegmann HVBK; Bosch-Traberg H; Startseva E; Zinman B;
Diabetes Obes Metab; 2019 Nov; 21(11):2450-2458. PubMed ID: 31282028
[TBL] [Abstract][Full Text] [Related]
37. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract][Full Text] [Related]
39. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
[TBL] [Abstract][Full Text] [Related]
40. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
